Paul Tudor Jones Arcellx, Inc. Transaction History
Tudor Investment Corp Et Al
- $25.1 Billion
- Q4 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Arcellx, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 3,600 shares of ACLX stock, worth $233,136. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,600
Previous 4,409
18.35%
Holding current value
$233,136
Previous $368,000
25.54%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ACLX
# of Institutions
224Shares Held
45.1MCall Options Held
434KPut Options Held
433K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$283 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$243 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$228 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$225 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$216 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.84B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...